Leerink Partners Initiates Coverage On Q32 Bio with Outperform Rating, Announces Price Target of $54
Portfolio Pulse from Benzinga Newsdesk
Leerink Partners has initiated coverage on Q32 Bio (NASDAQ:QTTB) with an Outperform rating and a price target of $54.
May 21, 2024 | 12:55 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Leerink Partners has initiated coverage on Q32 Bio with an Outperform rating and a price target of $54, indicating a positive outlook for the stock.
The initiation of coverage with an Outperform rating and a specific price target of $54 by a reputable analyst firm like Leerink Partners is likely to boost investor confidence and positively impact the stock price of Q32 Bio in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100